Colorectal cancer, a leading cause of cancer-related morbidity and mortality worldwide, has long presented therapeutic challenges due to the suppressive tumor microenvironment that dampens immune responses. Traditional vaccines targeting cancer antigens often falter as tumor-associated macrophages (TAMs) tend to adopt a phenotype that supports tumor progression rather than elimination. The new study, led by Hamdan, Gandolfi, and D’Alessio, strategically targets this hurdle by inducing “trained immunity” in macrophages, essentially reprogramming them to adopt a tumoricidal phenotype that synergizes with vaccine efforts.

Trained immunity refers to a form of long-term activation of innate immune cells characterized by epigenetic reconfigurations and metabolic shifts that enhance the cells’ responsiveness to subsequent challenges. Unlike adaptive immunity, which relies on antigen-specific memory, trained immunity represents a non-specific and durable heightened state of readiness primarily orchestrated by innate immune cells such as macrophages and natural killer cells. This fundamental shift in understanding innate immune memory has sparked a revolution in immunology, pointing to new therapeutic paradigms.

The researchers exploited beta-glucans, naturally occurring polysaccharides found in the cell walls of fungi and certain bacteria, as potent inducers of trained immunity. Beta-glucans engage receptors like Dectin-1 on macrophages, triggering downstream signals that culminate in both epigenetic modifications — such as histone methylation and acetylation — and metabolic reprogramming, including enhanced glycolysis and mitochondrial respiration. These molecular events recalibrate macrophage function from a pro-tumoral to an anti-tumoral disposition.

Detailed mechanistic investigations revealed that glucan-primed macrophages undergo a coordinated network of gene expression changes, driven by key transcription factors and chromatin remodeling complexes. This epigenetic rewiring stabilizes a phenotype that produces pro-inflammatory cytokines and reactive oxygen species, simultaneously improving antigen presentation and cytotoxic activity. Concurrently, metabolic shifts toward aerobic glycolysis furnish the energetic and biosynthetic demands to sustain this activated state, emphasizing the intertwined nature of metabolism and epigenetics in trained immunity.

Crucially, when these metabolically and epigenetically trained macrophages were introduced into preclinical models of colorectal cancer, they significantly potentiated the therapeutic benefit of cancer vaccines targeting tumor-associated neoantigens. The trained macrophages not only improved the infiltration and activation of tumor-specific T cells but also modulated the tumor microenvironment, reducing immunosuppressive factors and enhancing the overall immune surveillance. This combinatorial approach led to delayed tumor progression and improved survival outcomes in experimental studies.

The implications of this research are expansive. By reframing macrophages from passive bystanders or tumor accomplices to empowered effectors, the study provides a blueprint for next-generation immunotherapies. Leveraging trained immunity bypasses some limitations of checkpoint inhibitors and adoptive cell therapies, offering a potentially safer and more broadly applicable modality. The biomolecular insights into epigenetic and metabolic pathways also open avenues for developing novel adjuvants or small molecules that mimic glucan’s effects.

Furthermore, the study illuminates the plasticity of macrophages within the tumor milieu, challenging prior paradigms that considered TAMs irreversibly skewed. The reversible nature of epigenetic and metabolic states underscores the therapeutic window available to re-educate macrophages in situ. This dynamic reprogramming can be exploited not only for enhancing vaccines but also for synergistic approaches with chemotherapy, radiotherapy, and other immunomodulators.

Addressing translational potential, the researchers also evaluated safety and dose-response parameters in preclinical models, observing minimal systemic toxicity, which is a significant step toward clinical applicability. The use of naturally derived beta-glucans provides an additional advantage in terms of biocompatibility and cost-effectiveness, paving the way for scalable manufacturing and distribution in clinical settings.

The study also outlines challenges ahead, such as understanding long-term effects of trained immunity induction to avoid potential inflammatory or autoimmune sequelae. The heterogeneity of patient tumors and immune landscapes poses a further hurdle that will require personalized approaches or combinatorial strategies to maximize efficacy. Nevertheless, this research marks a critical milestone in unraveling the complexity of immune-tumor interactions.

In the broader context of cancer immunotherapy, these findings reinforce the paradigm shift towards harnessing innate immunity alongside adaptive responses. The integration of epigenetic and metabolic modulation into immunotherapy design exemplifies the cutting-edge of precision medicine and systems immunology. Future research trajectories include exploring analogous trained immunity induction in other innate cell populations, optimizing vaccine formulations for enhanced synergy, and clinical trials that will test these findings in human patients.

This seminal work by Hamdan and colleagues epitomizes the translational potential of fundamental immunology discoveries. By bridging molecular mechanisms with therapeutic innovation, their study lays a foundation for novel cancer treatments that re-engineer the immune system’s first line of defense into a potent weapon against colorectal cancer. The impact of such approaches could herald a new era where durable, effective immunotherapies become accessible for a disease that has long eluded curative interventions.

In conclusion, the strategic induction of trained immunity through glucan-mediated epigenetic and metabolic reprogramming of macrophages represents a paradigm-shifting approach in oncology. By fundamentally altering the immune landscape within tumors, this approach enhances vaccine efficacy and offers significant hope for improved patient outcomes. As the field advances, the convergence of innate immune training, vaccine science, and epigenetic therapeutics will likely center stage in the fight against cancer, unlocking new frontiers in personalized and durable immunotherapy.

Subject of Research:
The study focuses on leveraging glucan-induced trained immunity to epigenetically and metabolically rewire macrophages, aiming to enhance the response to colorectal cancer vaccines.

Article Title:
Leveraging glucan-induced trained immunity for the epigenetic and metabolic rewiring of macrophages to enhance colorectal cancer vaccine response.

Article References:
Hamdan, F., Gandolfi, S., D’Alessio, F. et al. Leveraging glucan-induced trained immunity for the epigenetic and metabolic rewiring of macrophages to enhance colorectal cancer vaccine response. Nat Commun (2026). https://doi.org/10.1038/s41467-026-68466-5

Image Credits: AI Generated

Macrophages, a vital component of the innate immune system, are known for their capacity to engulf and destroy pathogens and abnormal cells, including tumor cells. Unlike T cells, which have been extensively studied and utilized in CAR-T therapies, macrophages offer unique therapeutic advantages due to their inherent presence in tumor microenvironments and their capacity to modulate immune responses. However, engineering macrophages to express CARs has historically presented formidable challenges, particularly regarding efficient delivery methods and sustained functionality.

The research team, led by Gu, K., Liang, T., Hu, L., and collaborators, has circumvented these challenges by leveraging the cutting-edge field of mRNA technology combined with lipid nanoparticle delivery systems. Their approach entails the intraperitoneal injection of mRNA encapsulated within lipid nanoparticles tailored for uptake by peritoneal macrophages. Upon internalization, the mRNA drives the transient expression of CAR molecules on macrophages, thereby reprogramming their targeting capabilities against tumor-specific antigens.

This strategy contrasts sharply with ex vivo modification techniques, which require isolating immune cells from the patient, genetically modifying them in laboratory settings, and reinfusing them—a cumbersome process with logistical and cost barriers. Intraperitoneal programming allows for direct in vivo transformation of macrophages, vastly simplifying the therapeutic procedure and potentially broadening accessibility to CAR-macrophage therapies.

Technical validation involved a series of rigorous experiments demonstrating efficient mRNA delivery and CAR expression within macrophages harvested from treated models. The lipid nanoparticles exhibited optimal physicochemical properties, including size, charge, and stability, facilitating successful fusion with the cell membranes and endosomal escape of mRNA. The transient nature of mRNA expression also offers safety advantages by limiting prolonged CAR expression, thus mitigating risks of off-target effects and cytokine release syndromes commonly associated with persistent CAR cell therapies.

From an immunological perspective, the reprogrammed macrophages exhibited enhanced phagocytic activity against cancer cells expressing target antigens without eliciting excessive inflammatory responses. These tailored CAR macrophages effectively infiltrated tumor sites, overcoming the immunosuppressive tumor microenvironment that often inhibits immune cell activity. Notably, intraperitoneal administration resulted in superior local concentrations of CAR-macrophages within peritoneal tumors, a critical factor for effective tumor eradication.

The versatility of this platform is evidenced by its adaptability to various tumor types depending on the CAR design encoded within the mRNA. By merely altering the antigen recognition domain in the CAR construct, this method is capable of targeting a broad spectrum of malignancies, including those resistant to conventional therapies. The rapid manufacturing turnaround time and modularity make it an attractive candidate for personalized medicine applications, where therapy is tailored to the patient’s unique tumor antigen profile.

Advanced imaging and flow cytometry analyses further corroborated the systemic safety of this intervention. The confined intraperitoneal delivery minimized systemic exposure to nanoparticles and CAR-modified macrophages, reducing the probability of adverse systemic immune reactions. Additionally, pharmacokinetic profiling revealed that the CAR expression was transient, subsiding within a therapeutically sufficient window to allow effective tumor clearance while diminishing prolonged immune activation.

Beyond direct tumor killing, these engineered macrophages also demonstrated the capacity to modulate the immune hierarchy by influencing T cell responses. By secreting pro-inflammatory cytokines and presenting tumor antigens, CAR macrophages stimulated adaptive immunity, creating an immunological cascade that further amplified antitumor effects. This dual action—direct phagocytosis combined with immune system engagement—marks a significant leap in cancer immunotherapy design.

This research highlights the enormous therapeutic potential of intraperitoneal mRNA LNP delivery systems in circumventing the limitations of CAR-T therapy, including tumor antigen escape and T cell exhaustion. Macrophages, being resilient to the hostile tumor microenvironment, can sustain their antitumor functions more effectively when engineered in situ via this cutting-edge platform. Early preclinical models showed promising tumor regression outcomes, setting the stage for expedited translation into clinical trials.

Importantly, this study also opens pathways for exploring similar mRNA-based reprogramming of other innate immune cells, broadening the scope and impact of cancer immunotherapy. The ethical and manufacturing advantages of avoiding viral vectors and permanent genetic modification present a transformative shift in the therapeutic landscape, blending precision medicine with scalable drug development processes.

As mRNA technologies mature post the COVID-19 pandemic advances, their application in oncology marks one of the most salient frontiers today. The adaptability, safety profiles, and transient expression kinetics of mRNA encoded therapies align perfectly with the dynamic and heterogenous nature of tumors. The future promise of intraperitoneal LNP-mediated CAR macrophage therapy may well yield new hope for patients with notoriously difficult-to-treat cancers.

While challenges remain, including optimizing dosing regimens, enhancing LNP targeting specificity, and comprehensively evaluating long-term safety, this research sets a high benchmark. The capacity to program immune cells internally using non-viral, lipid-based mRNA vectors represents a technical revolution poised to accelerate development timelines and improve patient outcomes.

This pioneering work, reported in Nature Communications (2025), represents a formidable stride toward realizing the full potential of immune system engineering for cancer therapy. By harnessing the innate power of macrophages and the flexibility of mRNA lipid nanoparticle delivery, researchers are blazing a trail toward more effective, accessible, and safer immunotherapies capable of transforming oncologic care paradigms worldwide.

As clinical translation efforts begin, the oncology and immunology communities eagerly anticipate the impact of intraperitoneal mRNA LNP programming on patient survival and quality of life. This breakthrough approach underscores a broader paradigm shift in using biodegradable, non-integrative nucleic acid delivery for precise and adaptable immune interventions, laying the groundwork for a new era in cancer treatment innovation.

Subject of Research:
Intraperitoneal programming of chimeric antigen receptor (CAR) macrophages using mRNA lipid nanoparticles to enhance cancer immunotherapy efficacy.

Article Title:
Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy

Article References:
Gu, K., Liang, T., Hu, L. et al. Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy. Nat Commun (2025). https://doi.org/10.1038/s41467-025-67674-9

Image Credits:
AI Generated

Central to this discovery is the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway, a fundamental component of the innate immune system responsible for detecting aberrant double-stranded DNA (dsDNA) within the cytoplasm. Under normal conditions, the presence of cytosolic dsDNA acts as an alarm signal, activating cGAS which catalyzes the synthesis of cyclic GMP-AMP (cGAMP). This molecule subsequently engages STING, triggering a cascade of inflammatory and antiviral responses that prime immune cells to attack infected or damaged cells.

Intriguingly, many cancer cells harbor excessive amounts of cytosolic dsDNA due to genomic instability yet evade immune detection by silencing the cGAS-STING axis. This evasion permits tumors to thrive unchallenged within the immunosuppressive milieu of the tumor microenvironment. Recognizing this paradox, the Mass General Brigham scientists devised a method to reawaken this dormant immune sensor pathway directly within tumor cells, effectively turning cancer cells into producers of immunostimulatory signals.

The team achieved this by employing lipid nanoparticle (LNP) delivery systems to introduce messenger RNA (mRNA) encoding cGAS into melanoma tumor cells cultured in vitro. This genetic intervention restored cGAS expression, enabling cancer cells to detect cytosolic dsDNA and ramp up production of cGAMP. Importantly, the elevated levels of cGAMP were not confined to the cancer cells but were actively exported into the extracellular space, facilitating paracrine activation of surrounding immune cells.

This mechanism was confirmed when immune cells exposed to conditioned media from cGAS-reconstituted tumor cells exhibited clear markers of activation, indicating that tumor-derived cGAMP serves as a potent immunotransmitter capable of priming the immune microenvironment. The researchers then translated their findings to in vivo models, demonstrating that intratumoral administration of cGAS mRNA LNPs triggered profound immune activation, sharply slowed tumor progression, and extended survival in mice bearing aggressive melanoma tumors.

Adding another layer of clinical relevance, the study revealed that combining cGAS restoration therapy with immune checkpoint blockade—currently a frontline cancer immunotherapy—yielded synergistic effects, enhancing tumor control and immunotherapeutic efficacy beyond either treatment alone. This combinatorial strategy effectively converted “cold” tumors, which typically lack immune cell infiltration, into “hot” tumors marked by robust immune engagement.

The implications of these findings are both profound and wide-ranging. By hijacking cancer cells to manufacture and export immunostimulatory molecules, this modality circumvents several mechanisms of tumor immune evasion and remodels the tumor microenvironment to favor antitumor immunity. More broadly, the approach suggests a novel paradigm wherein tumor cells are repurposed from silent accomplices into active agents of their own demise.

From a mechanistic standpoint, this work sheds critical light on the plasticity of tumor-immune interactions, revealing that the innate immune signaling machinery within cancer cells can be pharmacologically restored to unleash powerful downstream effects on adaptive immunity. The utilization of mRNA-LNP technology to achieve precise intracellular delivery further exemplifies the transformative potential of RNA therapeutics in oncology.

Beyond oncology, the authors speculate that analogous strategies could be harnessed to enhance vaccine responses by manipulating endogenous cGAS-STING signaling pathways in target cells, opening exciting new avenues in infectious disease immunotherapy and vaccine development. The therapeutic versatility of this approach, combined with its capacity to synergize with existing immunotherapies, underscores its promise for future clinical translation.

While challenges remain in optimizing delivery systems, dosing regimens, and minimizing potential off-target effects, the breakthrough represents a paradigm shift in the design of cancer immunotherapies, emphasizing intracellular reprogramming of tumor cells rather than solely targeting immune effectors. This reversal of conventional wisdom could accelerate the advent of next-generation treatments that are both potent and specific.

Notably, the study emerged from an integrated academic health care system blending cutting-edge research and clinical expertise, reflecting the collaborative, multidisciplinary efforts required to translate fundamental insights into transformative therapies. Leading the effort, Dr. Natalie Artzi and her colleagues harnessed expertise in molecular biology, immunology, nanotechnology, and oncology to drive innovation.

In summary, the restoration of cGAS within tumor cells emerges as a powerful tool that reactivates innate immune sensing and orchestrates a robust antitumor response via tumor-cell generated cGAMP. This discovery paves the way for a revolutionary cancer immunotherapy paradigm with immense potential to improve outcomes for patients facing deadly malignancies.

Subject of Research: Cells
Article Title: Restoration of cGAS in tumor cells promotes antitumor immunity via transfer of tumor-cell generated cGAMP
News Publication Date: 3-Nov-2025
Web References: https://www.massgeneralbrigham.org/, https://www.pnas.org/doi/10.1073/pnas.2409556122
References: Cryer, A M et al. “Restoration of cGAS in tumor cells promotes antitumor immunity via transfer of tumor-cell generated cGAMP” PNAS DOI: 10.1073/pnas.2409556122
Keywords: Cancer cells, Cancer, Oncology, Cancer immunotherapy, Medical treatments